Narwhal Capital Management Has $18.96 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Narwhal Capital Management grew its stake in Eli Lilly and Company (NYSE:LLY) by 18.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 21,403 shares of the company’s stock after buying an additional 3,407 shares during the period. Eli Lilly and Company accounts for about 1.7% of Narwhal Capital Management’s holdings, making the stock its 13th largest position. Narwhal Capital Management’s holdings in Eli Lilly and Company were worth $18,962,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. M&G Plc acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $8,896,000. Virtu Financial LLC acquired a new stake in Eli Lilly and Company during the first quarter worth $2,138,000. China Universal Asset Management Co. Ltd. increased its holdings in Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares during the period. Mutual Advisors LLC raised its stake in shares of Eli Lilly and Company by 404.8% in the 1st quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after buying an additional 50,197 shares in the last quarter. Finally, Private Advisor Group LLC lifted its holdings in shares of Eli Lilly and Company by 0.6% during the 1st quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock worth $59,345,000 after acquiring an additional 430 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.3 %

Shares of NYSE LLY opened at $909.15 on Wednesday. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The firm’s 50-day moving average is $921.67 and its 200-day moving average is $860.45. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The firm has a market capitalization of $864.06 billion, a PE ratio of 133.90, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Equities analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Guggenheim increased their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Wells Fargo & Company raised their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Bank of America upped their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Berenberg Bank upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.24.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.